Trials / Completed
CompletedNCT03134066
Neurocognitive Features of Patients With Treatment-Resistant Depression
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
There is an urgent need for novel and effective interventions for treatment-resistant depression (TRD). In previous studies, ketamine has been shown to rapidly reduce depressive symptoms; however, the exact mechanisms of action of ketamine remain unknown. There are some preliminary findings to suggest that ketamine may exert its antidepressant effects through promotion of neurogenesis in the dentate gyrus. The aim of this study is to help delineate the neurocognitive effects of ketamine exposure using a behavioral task (specifically, a pattern separation task) and a battery of other well-established cognitive measures. This is an assessment-only study, as we will be recruiting subjects to complete an assessment battery at two time points, before and after receiving ongoing ketamine administrations for at least four weeks.
Conditions
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-08-09
- Completion
- 2018-01-17
- First posted
- 2017-04-28
- Last updated
- 2020-03-11
Source: ClinicalTrials.gov record NCT03134066. Inclusion in this directory is not an endorsement.